Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution

Summary: Ritedose announced FDA approval to manufacture and distribute generic Tobramycin Inhalation Solution in the United States.

Full answer: The approval allows Ritedose to manufacture and distribute a preservative-free generic Tobramycin Inhalation Solution. The product is intended for qualifying adults and pediatric patients six years of age and older with infections caused by Pseudomonas aeruginosa. The medication also represents the first cystic fibrosis product added to the Ritedose portfolio.

Summary: Tobramycin Inhalation Solution is an aminoglycoside antibiotic administered through a nebulizer to treat certain serious bacterial infections.

Full answer: Tobramycin is used to address infections caused by susceptible bacteria, including Pseudomonas aeruginosa. This bacterium is commonly associated with chronic respiratory infections among people with cystic fibrosis. Patients should use the medication only as prescribed and follow the instructions supplied by their healthcare provider.

Summary: The product is indicated for qualifying patients six years of age and older with Pseudomonas aeruginosa infections.

Full answer: Pseudomonas aeruginosa can cause serious and persistent respiratory infections, particularly among people living with cystic fibrosis. The approved indication includes both adults and pediatric patients who are at least six years old. Treatment decisions should be made by a qualified healthcare professional based on the patient’s diagnosis and individual medical needs.

Summary: The preservative-free medication is packaged in 300-milligram, 5-milliliter ampules for administration through a nebulizer.

Full answer: Each ampule contains a unit of liquid medication intended to be delivered using an appropriate nebulizer device. Nebulization converts the solution into an inhalable mist that allows the medication to reach the respiratory system. Patients should follow the approved product labeling and the administration directions provided by their healthcare professional.

Summary: Tobramycin is Ritedose’s first cystic fibrosis product and expands what the company describes as the country’s largest nebulized drug portfolio.

Full answer: Adding Tobramycin extends the Ritedose respiratory portfolio into an important new treatment area. It allows the company to support patients managing serious bacterial infections associated with cystic fibrosis. The product also complements Ritedose’s existing portfolio of nebulized medications for respiratory conditions.

Summary: Ritedose Pharmaceuticals is responsible for marketing the generic Tobramycin Inhalation Solution.

Full answer: Ritedose Pharmaceuticals is the generics division of The Ritedose Corporation. The company licensed the product’s Abbreviated New Drug Application from Hikma Pharmaceuticals, allowing Ritedose to add the medication to its generic portfolio. Manufacturing and distribution are supported by Ritedose’s sterile production capabilities and pharmaceutical infrastructure.

Summary: Blow-Fill-Seal technology forms, fills, and seals sterile unit-dose containers within a continuous automated process.

Full answer: Blow-Fill-Seal technology is designed for the efficient production of sterile liquid medications, including respiratory solutions. Combining container formation, filling, and sealing within one controlled process reduces human intervention and opportunities for contamination. This makes the technology well suited to preservative-free inhalation solutions packaged in unit-dose ampules.

Summary: Ritedose invested in expanded facilities, cold-chain processes, and an additional packaging line.

Full answer: These investments strengthened the company’s ability to manufacture, package, store, and distribute sterile pharmaceutical products. Expanded infrastructure provides additional capacity for a growing portfolio of respiratory and ophthalmic medications. The improvements also support the specialized handling and logistical requirements associated with different pharmaceutical products.

Summary: Producing Tobramycin in the United States can expand domestic capacity and reduce reliance on more vulnerable supply arrangements.

Full answer: Reliable domestic manufacturing can help pharmaceutical companies respond more effectively to patient demand and potential supply disruptions. Adding a U.S.-produced broad-spectrum antibiotic strengthens the available manufacturing base for an important respiratory therapy. It also supports Ritedose’s broader goal of providing dependable access to critical medications.

Summary: Ritedose also announced generic Formoterol Fumarate Inhalation Solution and an additional concentration of Albuterol Sulfate Inhalation Solution.

Full answer: Ritedose received approval in April 2025 to manufacture generic Formoterol Fumarate Inhalation Solution for the maintenance treatment of chronic obstructive pulmonary disease. In March, the company announced approval for Albuterol Sulfate Inhalation Solution 0.5 percent for qualifying patients experiencing bronchospasm or reversible obstructive airway disease. Together with Tobramycin, these additions expanded Ritedose’s nebulized medication portfolio.